ADOC regimen: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[ | {{PAGENAME}} refers to an immunochemotherapy regimen consisting of [[Doxorubicin|doxorubicin (Adriamycin)]], [[Cisplatin|cisplatin (cis-Diamminedichloroplatinum)]], [[Vincristine|vincristine (Oncovin)]], [[cyclophosphamide]] used to treat [[Thymoma|invasive thymoma]].<ref name="pmid2049749">{{cite journal| author=Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F et al.| title=Chemotherapy for invasive thymoma. A 13-year experience. | journal=Cancer | year= 1991 | volume= 68 | issue= 1 | pages= 30-3 | pmid=2049749 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2049749 }} </ref> | ||
==Regimen== | ==Regimen== | ||
| Line 16: | Line 16: | ||
==Indications== | ==Indications== | ||
* [[Thymoma]]<ref name="pmid2049749">{{cite journal| author=Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F et al.| title=Chemotherapy for invasive thymoma. A 13-year experience. | journal=Cancer | year= 1991 | volume= 68 | issue= 1 | pages= 30-3 | pmid=2049749 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2049749 }} </ref> | * [[Thymoma|Invasive thymoma]]<ref name="pmid2049749">{{cite journal| author=Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F et al.| title=Chemotherapy for invasive thymoma. A 13-year experience. | journal=Cancer | year= 1991 | volume= 68 | issue= 1 | pages= 30-3 | pmid=2049749 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2049749 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
Revision as of 20:18, 27 February 2015
|
WikiDoc Resources for ADOC regimen |
|
Articles |
|---|
|
Most recent articles on ADOC regimen Most cited articles on ADOC regimen |
|
Media |
|
Powerpoint slides on ADOC regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on ADOC regimen at Clinical Trials.gov Clinical Trials on ADOC regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on ADOC regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on ADOC regimen Discussion groups on ADOC regimen Patient Handouts on ADOC regimen Directions to Hospitals Treating ADOC regimen Risk calculators and risk factors for ADOC regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for ADOC regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
ADOC regimen refers to an immunochemotherapy regimen consisting of doxorubicin (Adriamycin), cisplatin (cis-Diamminedichloroplatinum), vincristine (Oncovin), cyclophosphamide used to treat invasive thymoma.[1]
Regimen
D – Cisplatin (Cis-Diamminedichloroplatinum)
Indications
References
- ↑ 1.0 1.1 Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F; et al. (1991). "Chemotherapy for invasive thymoma. A 13-year experience". Cancer. 68 (1): 30–3. PMID 2049749.